Inflammation-Induced Depressed Mood: The Role of Social Neurocognitive Mechanisms
| Status: | Recruiting |
|---|---|
| Conditions: | Depression |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 50 |
| Updated: | 5/5/2014 |
| Start Date: | March 2011 |
| Contact: | Ivana Jevtic, B.A. |
| Email: | dzvana@ucla.edu |
| Phone: | (310) 825-0658 |
Depressive disorders occur at a high rate in patients with inflammatory disorders, with a
point prevalence of 15-29%, which is two to three times greater than that observed in the
general population. Substantial evidence has shown that inflammation and increases in
proinflammatory cytokine activity play a critical role in the onset and perpetuation of
depression and depressive symptoms (e.g. insomnia, fatigue) in those who are co-morbid for
inflammatory disorders. Consistent with this, experimental work has shown that an
inflammatory challenge can increase depressed mood in an otherwise healthy sample. Based on
these findings, there has been a growing interest in whether inflammatory processes can
contribute to depression in a causal manner and how these effects might occur.
Given the observation that inflammatory processes trigger social withdrawal, coupled with
evidence that feelings of 'social disconnection' play a critical role in the onset and
perpetuation of (non-inflammatory forms of) depression, it is surprising that the social
psychological consequences of inflammation and their contribution to depression have not
been more fully explored. Here, we suggest that inflammation may increase feelings of social
disconnection and that these social psychological changes may be an important contributor to
inflammation-associated depression. Indeed, preliminary data demonstrated that an
experimentally-induced inflammatory challenge (endotoxin) led to increases in self-reported
feelings of social disconnection (e.g., "I feel disconnected from others") in addition to
increases in depressed mood. Aside from these findings, however, there are no studies that
have explored the effect of inflammatory processes on social experience in humans. The
over-arching objective of this proposal is to explore the experiential and neural correlates
of inflammatory-induced changes in social experience (e.g., feelings of social
disconnection), which may provide a critical missing link in understanding the relationship
between inflammation and depression.
Participants (n=100) will be randomly assigned to receive either endotoxin or placebo and
will then be monitored for the next six hours. Blood draws to assess cytokine levels as well
as self-reported feelings of social disconnection and depressed mood will be collected
hourly. In addition, at the time of peak cytokine response, participants will complete a
neuroimaging session to examine the effect of inflammatory challenge on neural sensitivity
to social rejection and social acceptance. It is hypothesized that endotoxin will increase
feelings of social disconnection over time, and that the underlying neural sensitivities
that give rise to these feelings (e.g., increased neural sensitivity to social rejection;
decreased neural sensitivity to social acceptance) will contribute to inflammatory-induced
depressed mood.
point prevalence of 15-29%, which is two to three times greater than that observed in the
general population. Substantial evidence has shown that inflammation and increases in
proinflammatory cytokine activity play a critical role in the onset and perpetuation of
depression and depressive symptoms (e.g. insomnia, fatigue) in those who are co-morbid for
inflammatory disorders. Consistent with this, experimental work has shown that an
inflammatory challenge can increase depressed mood in an otherwise healthy sample. Based on
these findings, there has been a growing interest in whether inflammatory processes can
contribute to depression in a causal manner and how these effects might occur.
Given the observation that inflammatory processes trigger social withdrawal, coupled with
evidence that feelings of 'social disconnection' play a critical role in the onset and
perpetuation of (non-inflammatory forms of) depression, it is surprising that the social
psychological consequences of inflammation and their contribution to depression have not
been more fully explored. Here, we suggest that inflammation may increase feelings of social
disconnection and that these social psychological changes may be an important contributor to
inflammation-associated depression. Indeed, preliminary data demonstrated that an
experimentally-induced inflammatory challenge (endotoxin) led to increases in self-reported
feelings of social disconnection (e.g., "I feel disconnected from others") in addition to
increases in depressed mood. Aside from these findings, however, there are no studies that
have explored the effect of inflammatory processes on social experience in humans. The
over-arching objective of this proposal is to explore the experiential and neural correlates
of inflammatory-induced changes in social experience (e.g., feelings of social
disconnection), which may provide a critical missing link in understanding the relationship
between inflammation and depression.
Participants (n=100) will be randomly assigned to receive either endotoxin or placebo and
will then be monitored for the next six hours. Blood draws to assess cytokine levels as well
as self-reported feelings of social disconnection and depressed mood will be collected
hourly. In addition, at the time of peak cytokine response, participants will complete a
neuroimaging session to examine the effect of inflammatory challenge on neural sensitivity
to social rejection and social acceptance. It is hypothesized that endotoxin will increase
feelings of social disconnection over time, and that the underlying neural sensitivities
that give rise to these feelings (e.g., increased neural sensitivity to social rejection;
decreased neural sensitivity to social acceptance) will contribute to inflammatory-induced
depressed mood.
Inclusion Criteria:
- Participants will be required to be in good general health (as evaluated during the
phone and in-person screening sessions described below), and to be between 18-50
years of age. All participants will be required to be fluent in English and to be
right-handed.
Exclusion Criteria:
- Following a structured telephone interview, prospective participants with the
following conditions will not advance to the in-person screening session:
claustrophobia or presence of metal in their body (relevant for the neuroimaging
component of the study), pregnant or planning to become pregnant in the next 6
months, presence of chronic mental or physical illness, history of allergies,
autoimmune, liver, or other severe chronic diseases, current and regular use of
prescription medications, nightshift work or time zone shifts (> 3hrs) within the
previous 6 weeks, or previous history of fainting during blood draws.
Furthermore, the absence of significant health problems or medication use history will be
confirmed by an in-person screening session. Any participant who has any of the following
conditions will be ineligible for the study: Medical conditions. (1) presence of co-morbid
medical conditions not limited to but including cardiovascular (e.g., history of acute
coronary event, stroke) and neurological diseases (e.g., Parkinson's disease), as well as
pain disorders; (2) presence of co-morbid inflammatory disorders such as rheumatoid
arthritis or other autoimmune disorders; (3) presence of an uncontrolled medical condition
that is deemed by the investigators to interfere with the proposed study procedures, or to
put the study participant at undue risk; (4) presence of chronic infection, which may
elevate proinflammatory cytokines; (5) presence of an acute infectious illness in the two
weeks prior to an experimental session. Psychiatric Disorders. (6) current and/or lifetime
history of a major Depressive Disorder or other DSM-IV psychiatric disorder (e.g.
substance dependence) due to the known effects of major depression and/or substance
dependence on inflammation. (Absence of a psychiatric diagnosis will be based on a
structured psychiatric interview (Structured Clinical Interview for DSM-IV Diagnosis:
SCID; First et al., 1996).) Medication and substance use. (7) current and/or past regular
use of hormone-containing medications including steroids; (8) current and/or past regular
use of non-steroid anti-inflammatory drugs; (9) current and/or past regular use of immune
modifying drugs that target specific immune responses such as TNF antagonists; (10)
current and/or past regular use of analgesics such as opioids; (11) current and/or past
regular use of psychotropic medications, including selective serotinergic reuptake
inhibitors, antidepressants, anxiolytics, hypnotics, sedatives and barbiturates. Health
factors. (12) current smokers or excessive caffeine users (>600 mg/day) because of known
effects on proinflammatory cytokine levels; (13) body mass index (BMI) greater than 35,
(14) shows evidence of drug use from a positive urine test, (15) has a positive pregnancy
test, if female, or (16) shows any abnormalities on screening laboratory tests.
We found this trial at
1
site
Click here to add this to my saved trials
